<unk>  undergoes extensive metabolism to several inactive metabolites in human beings, mainly methylhydroxygliclazide and carboxygliclazide. CYP2C9 is involved in the formation of hydroxygliclazide in human liver microsomes and in a panel of recombinant human P450s in vitro. But the pharmacokinetics of<unk>  MR are affected mainly by CYP2C19 genetic polymorphism instead of CYP2C9 genetic polymorphism.
Gliclazide
Glibenclamide
Linaclotide
Liranaftate
Lobeglitazone
Miglitol
Linagliptin
Saxagliptin